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Abstract
Background: Pulmonary hypertension (PH) is a lethal disease that is associated with characteristic histological abnormalities
of the lung vasculature and defects of angiopoetin-1 (ANG-1), TIE-2 and bone morphogenetic protein receptor (BMPR)-
related signalling. We hypothesized that if these signalling defects cause PH generically, they will be readily identifiable
perinatally in congenital diaphragmatic hernia (CDH), where the typical pulmonary vascular changes are present before
birth and are accompanied by PH after birth.
Methods: CDH (predominantly left-sided, LCDH) was created in Sprague-Dawley rat pups by e9.5 maternal nitrofen
administration. Left lungs from normal and LCDH pups were compared at fetal and postnatal time points for ANG-1, TIE-2,
phosphorylated-TIE-2, phosphorylated-SMAD1/5/8 and phosphorylated-ERK1/2 by immunoprecipitation and Western
blotting of lung protein extracts and by immunohistochemistry on lung sections.
Results: In normal lung, pulmonary ANG-1 protein levels fall between fetal and postnatal life, while TIE-2 levels increase.
Over the corresponding time period, LCDH lung retained normal expression of ANG-1, TIE-2, phosphorylated-TIE-2 and,
downstream of BMPR, phosphorylated-SMAD1/5/8 and phosphorylated-p44/42.
Conclusion: In PH and CDH defects of ANG-1/TIE-2/BMPR-related signalling are not essential for the lethal vasculopathy.
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Introduction
Pulmonary arterial hypertension (PH) remains a lethal disease:
understanding its pathogenesis is a key priority in the search for
effective therapies. Receptors for the TGF-beta super-family
appear to play pivotal roles since mutations in the genes for bone
morphogenetic protein receptor 2 (bmpr2) and anaplastic lympho-
ma kinase-1 (ALK-1) are implicated in familial PAH [1–3]. Even
in non-familial PAH, altered BMPR-2 signalling may result from
reduced pulmonary expression of BMPR-1A (with which BMPR-2
normally heterodimerizes for function) [4]. Reduced BMPR-1A
expression is induced in vitro by vascular growth factor,
angiopoetin-1 (ANG-1) signalling through TIE-2; elevations in
both of these are strongly correlated with disease severity in non-
familial PAH lung [4]. Increased ANG-1/TIE-2 signalling is
therefore proposed to interfere indirectly with BMPR-2 activity to
cause non-familial PH. Conversely, however, the ANG-1 and
TIE-2 changes are argued by others to result from, rather than
cause, PH [5–7].
Given these contrasting views, we sought to test if dysregulated
ANG-1/TIE-2/BMPR-related signalling is required for PH.
Human newborns with congenital diaphragmatic hernia (CDH)
frequently die due to refractory PH despite inhaled nitric oxide
(iNO) and extracorporeal membrane oxygenation (ECMO) [8,9].
We sought to test ANG-1/TIE-2/BMPR-related signalling in an
experimental rodent model of CDH induced by maternal
administration of nitrofen [10]. Resulting CDH fetuses and
newborns have hypoplastic lungs featuring diminished airway
and vascular branching, reduced cell proliferation, abnormal
growth factor responses and heparan sulphate co-factor expres-
sion, altered smooth muscle contractility and Ca2+ signalling, as
well as striking histological features of PH in the vasculature [10–
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e3536421]. Therefore, if dysregulated ANG-1/TIE-2/BMPR-related
signalling really is a significant driver of PH, we hypothesize that
such dysfunction should be apparent prenatally in the nitrofen
CDH model.
Materials and Methods
Animal Model: Creation of CDH and Lung Harvest
All experiments were approved under the Animals - UK
Scientific Procedures Act 1986, project licence number PPL 40/
2293 and personal licence number PIL 40/8001. All efforts were
made to minimize suffering and all surgery was performed under
general anaesthesia. Time-mated Sprague-Dawley rats were used
to create CDH. Day 0 of gestation was taken as the day of
discovery of a vaginal plug (term=day 22). To induce left CDH
(LCDH), 100 mg of nitrofen was dissolved in 2 mL of olive oil and
gavage fed to dams on day 9.5 of gestation [10]. Untreated
animals served as controls [22,23]. Fetal lungs were harvested on
days 17.5, 18.5, 20.5 and 21.5 of gestation (Figure 1). Control and
nitrofen exposed dams were given a lethal dose of intraperitoneal
sodium pentobarbital (100 mg/Kg) and fetuses delivered by
caesarean section. Since the vasculopathy is more severe in
ipsilateral CDH lung, left lungs were harvested from control and
LCDH fetuses [24]. Postnatal lung tissue was also harvested from
rat pups after a short period of air-breathing. These pups were
delivered by caesarean section with the dam under general
anaesthesia. Pups were rubbed dry to stimulate them and
encourage the onset of spontaneous breathing, placed in a warm
incubator at 30uC in ambient air and observed for respiratory
effort, movement and colour. Pups from both nitrofen treated and
control dams were sacrificed after fixed time periods (between
5 min and 1 h) by cervical dislocation. Control lung tissue from
older animals was harvested after cervical dislocation (12 h old
pups) or a lethal dose of intraperitoneal sodium pentobarbital (1
week old and adult rats). Lung tissue for Western blotting and
immunoprecipitation was snap-frozen in liquid nitrogen and
stored at 280uC. Lung tissue for immunohistochemistry was fixed
in 4% (w/v) paraformaldehyde in phosphate-buffered saline
pH 7.4 (PBS) for 4 h, washed in PBS and then cryoprotected by
immersion in 20% (w/v) sucrose overnight. The tissue was then
either embedded in gelatine (7.5% (w/v) gelatine in 15% (w/v)
sucrose in PBS) and coated with embedding medium or directly
coated with embedding medium before freezing by immersion in
pre-chilled isopentone at 240uC. Frozen fixed tissue was stored at
235uC until use.
Western blotting and immunoprecipitation
Western blotting of samples from e17.5 and e18.5 lungs
comprised 2–3 pooled left lungs. A single left lung was used as
an independent sample in older age groups with the exception of 1
week old and adult rats where a left lung fragment of equivalent
volume to an e21.5 left lung was used. Tissue was manually
homogenized in 0.5–1 mL of ice-cold modified radio-immuno-
precipitation assay (RIPA) buffer (50 mM Tris-HCl pH 7.4, 1%
(v/v) NP-40, 0.25% (w/v) Na-deoxycholate, 150 mM NaCl,
1 mM EDTA, 1 mM PMSF, 1 mM activated Na3VO4, 1 mM
NaF and 16 complete mini protease tablet/10 mL buffer). The
homogenate was left on ice for 10 min then centrifuged at
14,000 rpm for 10 min at 4uC. The insoluble material in the pellet
was discarded. Total protein content of the supernatant was
determined using a bicinchoninic acid kit based on the method
described by Smith et al. (1985) and total protein concentration of
the supernatant was adjusted to between 0.75 and 1.25 mg/mL
with RIPA buffer. Electrophoresis sample buffer (56, 250 mM
Tris-HCl pH 6.8, 10% (w/v) SDS, 5% (v/v) beta mercaptoeth-
anol, 10% (v/v) glycerol, 0.01% (w/v) bromophenol blue) was
added to give a final 16concentration of buffer and the sample
was boiled for 5 min.
Samples containing approximately 24 mg of total lung protein
were separated in 8, 10 and 12% (w/v) polyacrylamide gels by
SDS-PAGE. A C6 BMP4-stimulated cell lysate was used as a
positive control for phosphorylated SMAD1/5/8 (p-SMAD1/5/8)
and phosphorylated ERK1/2 (p-ERK1/2). Separated polypep-
tides were electro-transferred onto nitrocellulose membrane.
Membranes were blocked by incubating in 5% (w/v) non-fat milk
solution/TRIS- or phosphate-buffered saline (TBS/PBS)/0.1%
(v/v) Tween-20 for 1 h at room temperature. Membranes were
then incubated with primary antibody at 4uC. Antibodies against
p-SMAD1/5/8 and p-ERK1/2 were used at 1:1000 dilution in
TBS/0.1% (v/v) Tween-20 with 2.5% (w/v) bovine serum
albumin (p-SMAD1/5/8) or 5% (w/v) non-fat milk (p-ERK1/
2). Antibodies against ANG-1 and TIE-2 were used at 1:1000
dilution in PBS/0.1% (v/v) Tween-20 with 5% (w/v) non-fat milk.
Following overnight incubation with primary antibody, mem-
branes were washed five times in TBS/0.1% (v/v) Tween-20
(TBS/T) over 25 min, then incubated with horse-radish peroxi-
dase (HRP) labelled anti-goat (ANG-1, TIE-2), anti-rabbit (p-
SMAD1/5/8) or anti mouse (p-ERK1/2) antibodies for 1 h at
room temperature. After a further wash cycle, membranes were
incubated with chemiluminescence reagent and immunoreactive
bands were imaged with the ChemiDoc XRS System using
Quantity-One software. After imaging, membranes probed for p-
ERK1/2 were incubated with stripping buffer (40 mM Tris-HCl
pH 6.8, 0.67% (w/v) SDS, 0.3% beta mercaptoethanol) for
30 min at room temperature, washed in TBS/T and re-incubated
overnight with antibodies against ERK1/2 or actin. Membranes
were re-washed and incubated with appropriate secondary
antibodies. All other membranes were simply washed, re-
incubated with anti-actin followed by the appropriate secondary
antibody. After a final wash cycle membranes were incubated with
chemiluminescence reagent and imaged, as described above.
Immunoprecipitation
Lung protein extracts from e20.5 and e21.5 (800–900 mg
protein) were made up to 400 mL with RIPA buffer. The protein
extract was incubated overnight with 40 mL of anti-phosphorylat-
ed tyrosine cross-linked to protein-A agarose beads (clone 4G10)
on a rotating wheel at 4uC. The samples were then centrifuged
(14,000 rpm, 10 min, 4uC), the supernatant discarded and the
agarose bead slurry washed with ice-cold RIPA buffer, then ice-
cold PBS to reduce detergent levels. The beads were re-suspended
in electrophoresis sample buffer to give a final 16concentration of
buffer and the mixture boiled for 5 minutes. Equal volumes of
supernatant were subjected to SDS-PAGE and Western blotting
with TIE-2 antibody.
Immunohistochemistry
Tissue sections 7 mM thick were cut using a cryostat and thaw-
mounted onto slides, dried at room temperature and re-frozen
until use. Slides for incubation with p-SMAD1/5/8 antibody were
incubated in antigen retrieval buffer (10 mM sodium citrate,
pH 6.0) at just below 100uC for 10 min, cooled in the buffer for
30 min then washed. Sections were incubated with blocking buffer
(PBS, 20% (v/v) goat serum) for 30 min then incubated overnight
at 4uC with p-SMAD1/5/8 antibody in buffer (PBS, 0.1% (v/v)
Tween-20, 5% (v/v) goat serum). Slides for incubation with TIE-2
antibody were incubated directly with blocking buffer (PBS, 20%
(v/v) rabbit serum) for 30 min then incubated overnight at 4uC
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doi:10.1371/journal.pone.0035364.g001
Figure 2. Western blots and graphs showing ANG-1 and actin immunoreactivity. Western blots showing ANG-1 and actin
immunoreactivity in control and LCDH lung (a). ANG-1 immunoreactivity in control (grey) and LCDH lung (white boxes) expressed as median
(bar) and inter-quartile ranges (box) (b). Statistical analysis found a significant linear trend (#) in the fall in ANG-1.
doi:10.1371/journal.pone.0035364.g002
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(v/v) rabbit serum). Slides were then washed in PBS and sections
incubated with fluoroscein isothiocyanate conjugated (FITC) anti-
goat antibodies (TIE-2) or anti-rabbit antibodies (p-SMAD1/5/8)
in PBS for 2 h. Following further washes the slides were mounted
in fluorescent mounting medium and visualized using fluorescence
and the appropriate filter. Control sections were treated as above
except the primary antibody was omitted.
For diaminobenzidine (DAB) staining, after incubation in
blocking buffer (TBS, 20% (v/v) serum) slides were incubated in
0.3% (v/v) hydrogen peroxide in TBS for 15 minutes to block
endogenous peroxide activity, then rinsed in TBS. Sections were
incubated overnight at 4uC with TIE-2 or p-SMAD1/5/8
antibody in buffer (TBS, 0.1% (v/v) Tween-20, 5% (v/v) serum).
The following morning slides were washed in TBS then sections
were incubated with biotin conjugated anti-goat or anti-rabbit
antibodies in TBS for 45 min, washed and then incubated with a
streptavidin-biotinylated peroxidase mixture for a further 45 min.
Slides were washed again before incubating with DAB (Fast 3,39-
diaminobenzidine tablet set) for 3–5 min and then thoroughly
rinsed with running water. Slides were lightly stained with Mayer’s
haemalum and 1% aqueous eosin before mounting with DPX
mounting medium and visualisation with light microscopy.
Control sections were treated as above except the primary
antibody was omitted.
Figure 3. Western blots and graphs showing TIE-2 and actin immunoreactivity. Western blots showing TIE-2 and actin immunoreactivity in
control and LCDH lung (a). TIE-2 immunoreactivity in control (grey) and LCDH lung (white boxes) expressed as median (bar) and inter-quartile ranges
(box) (b). Statistical analysis found a significant linear trend (#) in the rise in TIE-2.
doi:10.1371/journal.pone.0035364.g003
Figure 4. Photomicrographs showing TIE-2 immunoreactivity.
Photomicrographs showing similar TIE-2 immunoreactivity (brown DAB
staining) in the endothelium of rat pulmonary vasculature at gestation
e20.5 in (A) control lung (manification6100) and (B) LCDH lung (6100).
doi:10.1371/journal.pone.0035364.g004
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Rats were purchased from Charles River Ltd., UK. Nitrofen
was purchased from Zheijang Chemicals, China. Embedding
medium (Cryo-M-bed) was purchased from Bright Instrument
Company, Huntingdon, UK. Complete mini protease tablets were
purchased from Roche, Switzerland. The bicinchoninic acid Kit,
Tween-20, anti-actin antibody, FITC-conjugated anti-goat and
anti-rabbit antibodies and the Fast 3,39-diaminobenzidine tablet
set were purchased from Sigma-Aldrich, UK. Antibodies against
p-SMAD1/5/8, p-ERK1/2 and ERK1/2 were purchased from
Cell Signaling Technology, USA. The C6 BMP4-stimulated cell
lysate was donated by Cell Signaling Technology. Antibodies
against ANG-1 and TIE-2 were purchased from R & D Systems,
UK. The nitrocellulose membrane (Hi-bond) was purchased from
Amersham Biosciences, GE Healthcare UK Ltd. SuperSignal
West Dura Substrate chemiluminescence reagent was purchased
from Pierce, UK. The anti-phosphorylated tyrosine antibody
cross-linked to protein-A agarose beads (clone 4G10) was
purchased from Upstate, Millipore Corporation, USA. Biotin
conjugated anti-goat and anti-rabbit antibodies, and the strepta-
vidin-biotinylated peroxidase mixture was purchased from Dako,
Denmark.
Data analysis
Photon output originating from individual bands of immuno-
reactivity was recorded as intensity per mm2 (INT/mm2) and only
measurements that were not saturated, as determined by the
ChemiDoc imager, were used. Background intensity for each
membrane was measured and subtracted from the intensity
measurements recorded from immunoreactive bands to give
normalised density. Protein level per immunoreactive band was
calculated relative to actin level to give normalised relative protein
levels. Each experiment was repeated between 4 and 7 times and
normalised relative band densities reported as medians and inter-
quartile ranges (IQR). Statistical differences between median band
density for the groups (control and LCDH) at and between each
gestational time-point were determined by Mann-Whitney U test
using SPSS version 13. Analysis of the trends seen according to
gestational age was done by Oneway ANOVA with polynomial
contrasts (SPSS version 13). A p-value of ,0.05 was considered
significant.
Figure 5. Western blot and graph showing phosphorylated (p) TIE-2 immunoreactivity. Western blot showing p-TIE-2 immunoreactivity in
e20.5 lung in three contempraneously prepared sample pairs, 1,2 and 3 (C=control, H=LCDH). Total TIE-2 expression in sample pair 3 is shown (*C3
& *H3) as a positive control (a). Normalised p-TIE-2 immunoreactivity in control (grey) and LCDH lung (white boxes) expressed as median and inter-
quartile ranges (b).
doi:10.1371/journal.pone.0035364.g005
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ANG-1 and TIE-2 are developmentally regulated but
unaltered in perinatal CDH lung
To test if increased ANG-1/TIE-2 activity suppresses BMPR
signalling to generate PH as postulated in human adult studies, we
first tested if ANG-1/TIE-2 activity was abnormally increased in
the perinatal CDH lung with its established pulmonary vascular
changes typical of PH. Immunoblotting with the antibody to
ANG-1 revealed a single band of immunoreactivity corresponding
to 75 kDa (Figure 2a). There was a significant change in ANG-1
protein level with the developmental stage of the lung (Figure 2b &
c). ANG-1 protein levels in control lung fall significantly from
e17.5 and e18.5 to a low level at e21.5. From the low level at e21.5
there is a marked rise by 12 h after birth. The ANG-1 level
detected in adult lung was significantly lower than in e17.5, e18.5
and e20.5 fetal lung, as well as being significantly lower than the
level recorded in 12 h old lung (Figure 2c). Statistical analysis of
the fall in ANG-1 between e17.5 and postnatal by Oneway
ANOVA found an unweighted linear trend F value of 6.87 with a
p value of 0.015, suggesting a significant linear trend. There was
no significant difference between the level of ANG-1 protein
between control and LCDH lung (Figure 2b). The decline of
ANG-1 protein levels in control lung between the early (e17.5) and
late fetal period (e21.5) was also mirrored in LCDH lung with a
significant linear trend (F value 12.38, p=0.002). Later postnatal
time-points could not be examined in LCDH lung, since survival
for nitrofen-exposed pups is usually less than 30 min.
Immunoblotting with an antibody to TIE-2 revealed a
dominant band of immunoreactivity corresponding to a size of
145 kDa (Figure 3a). There was a significant change in the level of
TIE-2 and the stage of development of the lung (Figure 3b & c).
TIE-2 levels in control lung rise significantly from low levels at
e17.5 to a high level in PN lung. From the high level in PN lung
there is a fall by 12 h of age and then TIE-2 levels rise to a
maximum in adult lung (Figure 3c). Statistical analysis of the rise in
TIE-2 between e17.5 and PN by Oneway ANOVA found an
unweighted linear trend F value of 21.16 with a p value of
,0.0001 suggesting a significant linear trend. There was no
significant difference between the level of TIE-2 protein between
control and LCDH lung (Figure 3b). Again, the same trend of a
rise in TIE-2 protein level was observed in LCDH lung between
the early fetal period (e17.5) and postnatal. Analysis of this trend in
LCDH lung also showed a significant linear trend (F value 13.17,
p=0.001).
Figure 6. Western blot and graph showing p-SMAD1/5/8 and actin immunoreactivity. Western blot showing p-SMAD1/5/8 and actin
immunoreactivity (+ve cell=positive control cell lysate, BMP stimulated C6 cells) (a). p-SMAD1/5/8 immunoreactivity in control (grey) and LCDH lung
(white boxes) expressed as median (bar) and inter-quartile ranges (box) (b).
doi:10.1371/journal.pone.0035364.g006
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comparable between normal and CDH lung: TIE-2 localised to
the endothelium in fetal (e20.5) and adult pulmonary arteries
(Figure 4) with no gross differences in immunohistochemical
staining intensity; phosphorylated (activated) TIE-2 protein levels
determined by Western blotting were not significantly different
between control and LCDH lung at e20.5 and e21.5 (Figures 5a &
b).
Signalling downstream of BMPR appears normal in
perinatal CDH lung
In the absence of pathological changes in ANG-1/TIE-2
signalling, we next tested if BMPR signalling was being
dysregulated by another pathway by comparing normal and
perinatal CDH lung for the pulmonary SMAD and ERK1/2
elements of downstream BMPR signalling. Immunoblotting with
antibody to p-SMAD1/5/8 revealed a dual band of immunore-
activity corresponding to a size of 55–60 kDa in control and
LCDH lung extracts, and the positive control cell lysate (Figure 6a).
There was no significant difference between the level of p-
SMAD1/5/8 protein between control and LCDH lung at any
gestation time studied (Figure 6b). p-SMAD1/5/8 immunoreac-
tivity was localised to the vascular endothelium and the airway
epithelium in fetal rat lung (Figure 7). High power images acquired
using diaminobenzidine staining (Figures 7 A & B) revealed
staining of the cytoplasm and nuclei of the endothelial cells of the
pulmonary vasculature. Low power images acquired using FITC
staining (Figures 7 C & D) revealed airway epithelial p-SMAD1/
5/8 staining, but vascular endothelial staining was not detected by
this method. There were no gross differences in localisation or
intensity of p-SMAD1/5/8 staining between control and LCDH
lung at e19.5 and e21.5.
Immunoblotting with antibody to p-ERK1/2 revealed two
bands of immunoreactivity corresponding to sizes of 42 and
44 kDa in control and LCDH lung extract (Figure 8a). Using actin
to calculate relative protein expression, there was no significant
difference between the level of p-ERK1/2 protein between control
and LCDH lung at the gestation times studied (Figure 8b). Using a
total ERK1/2 antibody to calculate the protein activity relative to
the total amount of ERK1/2 (Figure 8c), it was confirmed that
there was no significant difference between the level of p-ERK1/2
protein between control and LCDH lung.
Discussion
Pulmonary hypertension is associated with high mortality in
newborns, children and adults. Uncovering the signalling
abnormalities that underpin PH remains a key component in
the search for new and effective therapies. TGF-beta super family
signalling appears critical as familial PH is associated with not only
bmpr2 mutations but also alterations in other related pathways such
as ALK [1,2,3]. Signalling downstream of the TGF-beta super
family receptors includes SMADs and, in certain cell types,
mitogen-activated protein kinases (MAPKs) such as ERK1/2, with
some context-dependent variation [25,26]. Experimental PH and
bmpr2 insufficiency models appear to reduce SMAD signalling with
similar findings observed in humans with familial PH [27–33]. It is
noteworthy that upregulation of MAPKs in experimental PH
varies throughout the course of disease. Intriguingly, bmpr2 gene
therapy attenuates experimental PH even in the absence of bmpr2
mutations [34].
A unifying model of BMPR dysfunction to explain both familial
and non-familial PH has emerged from human data showing
enhanced ANG-1/TIE-2 signalling suppresses BMPR1A, and
hence BMPR2 activity in non-familial PH [4]. To evaluate this
further, it is critical to determine whether the signalling defects
observed in PH in this and other studies represent causal changes,
mere correlation or even a protective response to PH [5,6]. Given
the insidious onset of adult PH, it is not currently feasible to test
this in human subjects. Similarly debate persists about the
characteristic pathological changes observed in the pulmonary
vasculature and whether they are the cause of PH, or conversely, a
consequence of it.
Newborns with CDH frequently die as a result of refractory PH
[35,36]. Unlike those developing persistent pulmonary hyperten-
sion of the newborn (PPHN) from other causes (notably meconium
aspiration syndrome), infants with CDH do not respond
consistently well to inhaled nitric oxide (iNO) [8,37]. While this
may indicate the inherent heterogeneity of PH, the refractory
nature of PH in CDH suggests it may have more in common with
adult PH. Taking these concepts, it is striking to note that the
pulmonary vascular changes that are so characteristic of adult PH
are also present in prenatal CDH lung. This supports the view that
such vascular abnormalities precede and are perhaps causative of
PH. In view of these shared pathological defects, we sought to
determine if the signalling aberrations identified in adult humans
with PH could also be observed in prenatal and newborn CDH
lung. We sought to also explore whether such signalling defects
were responsible for PH.
To access prenatal and neonatal CDH lung, we utilised the
leading CDH experimental model which closely phenocopies
human CDH possessing both the characteristic pulmonary
vascular changes of PH and some abnormalities of endothelial
Figure 7. Photomicrographs showing p-SMAD1/5/8 immuno-
reactivity. Photomicrographs showing similar p-SMAD1/5/8 immuno-
reactivity (brown DAB staining) in the endothelium of rat pulmonary
vasculature in (A) control lung at gestation e19.5 (manification 6100)
and (B) LCDH lung, at gestation e19.5 (6100). p-SMAD1/5/8 immuno-
reactivity in the airway epithelium in (C) control lung at gestation e21.5
(manification 625) and (D) LCDH lung, at gestation e21.5 (625).
doi:10.1371/journal.pone.0035364.g007
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model, we have shown that the ANG-1/TIE-2/BMPR-related
signalling defects observed in adult PH patients are not present
prenatally or even in the newborn period despite the presence of
the shared pulmonary vasculopathy. We also demonstrated that
both pulmonary levels of ANG-1 and TIE-2 are developmentally
regulated with significant changes noted during the critical
transition of the pulmonary vasculature from prenatal to postnatal
life. Hence, while our data indicate that ANG-1/TIE-2 signalling
is not dysregulated as a cause of PH in CDH, this pathway may
still be crucially important in adaptations of the lung vasculature at
birth.
There are a number of important caveats to these findings.
Firstly, different species may intrinsically regulate ANG-1 and
TIE-2 differently through development [40]: hypoplastic human
fetal lung associated with a range of conditions including CDH
showed minimal gestational change in ANG-1 but a fall in TIE-2
[41]; in baboon lung both ANG-1 and TIE-2 mRNA levels have
been reported to rise during gestation [42]; in a murine CDH
model, raised ANG-1 protein levels were transiently observed in
late gestation lung but, in keeping with our observations, normal
levels returned after birth [26]. Secondly, we found striking p-
SMAD1/5/8 staining with FITC in large airway epithelium at the
time points studied. Vascular endothelial staining was only
detected with DAB stained tissue using high powered magnifica-
tion. Predominant airway staining has been described previously
and it is possible that most SMAD1/5/8 activity on Western
blotting was of airway rather than vascular origin [43,44]. Hence,
relevant changes in vascular SMAD1/5/8 activity may have been
masked by larger and invariant airway expression. Third, unlike
studies that have reported respectively either increased total lung
ERK1/2 activity or reduced ERK1/2 activity, we identified no
differences in ERK1/2 activation between normal and LCDH
lung [23,45]. Different experimental protocols and species
differences may underlie some of this variation, but our data
indicate that altered pulmonary ERK1/2 activity is not causative
in PH associated with CDH. A further observation herein reported
relates to the expression of activated protein levels relative to total
actin or total ERK1/2. Takahashi et al. reported activated protein
as a ratio of the total amount of ERK1/2 and concluded that
changes in MAPK activity were not due to induction of total
protein [28]. Further, our findings show that when levels of
activated ERK1/2 protein were measured relative to both actin
and total ERK1/2, we still detected no significant differences.
In summary, ANG-1 and TIE-2 are developmentally regulated
in perinatal lung and may participate in pulmonary adaptation to
extrauterine life. However, ANG-1/TIE-2/BMPR-related signal-
ling defects are not essential for the pulmonary vasculopathy
characteristic of PH in CDH. Therefore, therapies to reduce
elevated levels of ANG-1/TIE-2 signalling in adult humans with
Figure 8. Western blots and graphs showing p-ERK1/2, total ERK1/2 and actin immunoreactivity. Western blot showing p-ERK1/2, total
ERK1/2 and actin immunoreactivity (a). p-ERK1/2 immunoreactivity relative to actin (b) and total ERK1/2 (c) in control lung (grey boxes) and LCDH
lung (white boxes) expressed as median (bar) and inter-quartile ranges (box).
doi:10.1371/journal.pone.0035364.g008
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may be either epiphenomena or even protective responses.
Interestingly, ANG-1 is currently being tested therapeutically in
a range of conditions including myocardial infarction and sepsis
[46,47]. Even if such strategies to modulate ANG-1/TIE-2
signalling prove effective for adult PH, our findings indicate they
are likely to be ineffective in CDH and that the pathogenesis of
CDH related PH is sufficiently different from adult diseases to
warrant dedicated research endeavors for this unsolved problem.
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